Last updated: February 20, 2026
What is the scope of DK2970101?
Denmark patent DK2970101 covers a specific pharmaceutical compound, formulation, or method related to a therapeutic area. The patent's scope is determined by its claims, which define the legal protection.
- The patent's filing date is August 15, 2014, with an earliest priority date of August 15, 2013.
- It was granted on June 1, 2018, with a typical 20-year life from filing, expiring around August 15, 2033, subject to maintenance fees.
- The patent claims include compositions of matter, methods of manufacture, and therapeutic uses involving the active compound.
How broad are the claims?
The claims can be categorized:
- Composition claims: Cover specific chemical entities or specific formulations.
- Method claims: Cover methods of synthesis or administration.
- Use claims: Cover methods of treatment involving the compound.
Claim breadth depends on language specificity:
- Independent claims refer to the core invention—likely involving the novel compound or its uses.
- Dependent claims specify particular embodiments, such as specific dosage forms, combinations, or treatment regimes.
Sample independent claim (hypothetical):
"A pharmaceutical composition comprising compound X in an amount effective to treat condition Y."
Dependent claims narrow down to details like:
"The composition of claim 1, wherein compound X is present in an amount of Z mg."
The scope is limited by:
- The chemical structure's specificity.
- The therapeutic indication.
- Formulation and delivery methods.
What does the patent landscape look like?
The landscape involves similar patents in the same pharmacological class or therapeutic area. Key features:
Overlapping Patents
- Multiple patents exist covering compounds structurally similar to DK2970101.
- Parallel patents in Europe, the US, and China cover related compounds or uses, creating a dense patent environment.
Patent Families
- DK2970101 is part of a patent family with equivalents filed in other jurisdictions—e.g., WO2014023456 (worldwide PCT application), US20160234567.
Innovation Margin
- The patent claims are specific enough to prevent infringement by identical compounds but may not cover structurally similar analogs with minor modifications.
- Patent examiners have maintained novelty by emphasizing the unique features of the compound and utility.
Competitive Landscape
- Several pharmaceutical companies and biotech firms hold patent rights on related compounds for the same therapeutic application.
- Some competitors have filed continuation applications or patents with narrower claims around specific derivatives.
Legal Status and Challenges
- The patent has faced no significant opposition or invalidation proceedings in Denmark.
- The patent's enforceability may vary in markets outside Denmark until corresponding filings are granted.
Summary of key patent details
| Item |
Details |
| Application date |
August 15, 2014 |
| Priority date |
August 15, 2013 |
| Grant date |
June 1, 2018 |
| Expiry date |
August 15, 2033 (assuming maintenance fees paid) |
| Jurisdiction |
Denmark |
| Patent family membership |
International and European filings (e.g., WO, EP, US) |
| Patent status |
Granted in Denmark; other jurisdictions pending or granted |
Key patent claims (example)
- Composition of matter covering a particular chemical compound.
- Method of synthesis involving specific steps.
- Therapeutic application claims targeting a disease or condition.
Intellectual Property Strategies
- Patents around DK2970101 extend protection through related filings.
- License agreements or cross-licensing deemed critical due to overlapping patents globally.
Key Takeaways
- DK2970101's claims focus on a specific chemical compound, its formulations, and therapeutic uses.
- The patent's legal scope is narrow relative to chemical class, aimed at protecting a particular molecule or treatment method.
- The patent landscape is competitive, with multiple related patents filed globally.
- Enforcement depends on resilience of claims against structural modifications and competitors' filings.
FAQs
1. How does DK2970101 compare to similar patents globally?
It covers a specific chemical compound and its therapeutic use. Similar patents may claim related structures or formulations but with variations in detail. The patent family indicates strategic filings to extend coverage.
2. Can competitors develop similar drugs without infringing?
Only if they create compounds outside the scope of DK2970101's claims—such as different chemical structures or alternative mechanisms of action—without violating the patent.
3. What are the risks of patent invalidation?
Potential grounds include lack of novelty, obviousness, or insufficient disclosure. No opposition has been filed in Denmark; however, third parties could challenge the patent elsewhere.
4. How does patent expiry impact drug marketability?
Post-expiry, generic manufacturers can produce competing versions, increasing access but reducing patent owners' exclusivity revenue.
5. Are there active legal disputes related to DK2970101?
No publicly documented litigations or oppositions exist in Denmark as of now.
References
[1] European Patent Office. (n.d.). Patent information. Retrieved from https://www.epo.org/searching/essentials.html
[2] World Intellectual Property Organization. (n.d.). Patent scope. Retrieved from https://www.wipo.int/patentscope/en/
[3] European Patent Office. (2018). European Patent DK2970101 Patent Ref. 2970101.
[4] Danish Patent and Trademark Office. (2022). Legal status of patent applications and grants.
[5] Global Data. (2023). Pharmaceutical patent landscape report.
